x

Science

Pfizer to Spend $11.6B on Migraine Treatment Maker Biohaven

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area.

The New York vaccine and cancer drug maker said Tuesday it will use cash on hand to buy the remaining portion of migraine treatment developer Biohaven Pharmaceuticals it does not already own.

Pfizer will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has a nasal spray under development.

Pfizer Inc. brought in more than $14 billion in sales during the recently completed first quarter from its COVID-19 vaccine Comirnaty and its new pill treatment for the virus, Paxlovid.

Most of that came from Comirnaty, which also rang up nearly $37 billion in sales last year. But revenue from Comirnaty, which Pifzer developed with BioNTech, is expected to fade in the coming years, and Pfizer also faces the loss of patent protection for some key products in its broad portfolio over the next decade.

That includes Eliquis for preventing blood clots and strokes and the Prevnar 13 vaccine for preventing pneumonia and related bacterial diseases.

The company plans to have about $25 billion in sales by 2030 come from new business developments.

The deal announced Tuesday is a step in that direction. U.S. regulators approved Nurtec tablets for treating migraines in February 2020 and for preventing them about a year ago.

Nurtec ODT brought in nearly $124 million in sales in the first quarter, and Biohaven expects $825 to $900 million in product sales this year.

Last November, Pfizer said it would invest $350 million in Biohaven to help sell Nurtec OTD and the spray, zavegepant, outside the United States.

Pfizer said Tuesday the spray is on track for U.S. acceptance in the current quarter, and an oral gel version of it also is being developed for preventing chronic migraines.

The deal price announced Tuesday represents a 33% premium over Biohaven’s 90-day weighted average trading price of $111.70 for Biohaven Pharmaceutical Holding Co. Ltd., which is based in New Haven, Connecticut.

The deal for Biohaven also includes some other potential treatments in early stages of development.

Other elements of Biohaven’s late-stage development pipeline will go to a new, publicly traded company that keeps the Biohaven name.

The boards of both Pfizer and Biohaven have approved the sale, but Biohaven shareholders and regulators till need to ok it.

It is expected to close by early 2023, once the new company spinoff is completed.

Shares of Biohaven, which had tumble below $100 in recent weeks, soared about 70% before the opening bell to $141.50. Pfizer’s stock slipped.

RELATED

Young women diagnosed with breast cancer often must delay pregnancy for years while they take hormone-blocking pills.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Mitsotakis: Today’s Bill Comes to Define a New Field in Which Everyone Should Move

ATHENS - At the end of August 2022, I announced a legislative initative for the upgrading and modernisation of the protection, the operation of the security agencies and the operation of the communications and after the change in National Intelligence Service's (EYP) leadership and the establishment of double check to the legal intrusions," stated Prime Minister Kyriakos Mitsotakis addressing the parliament on Thursday during the debate on Justice Minstry's bill on the lifting of the communications confidentiality, cybersecurity and protection of the citizens' personal data.

DOHA, Qatar — Lionel Messi and Cristiano Ronaldo are not ready to say goodbye to the World Cup just yet.

ATHENS — A little-known Greek anarchist group has claimed responsibility for an arson attack on an Italian diplomat's car at her home in Athens.

ATHENS - Prime Minister Kyriakos Mitsotakis described his ambition and his vision for the technology sector to contribute 10% to Greece's GDP in five years during his speech on Thursday at the inauguration of the first phase of the largest data centre in terms of capacity that has been manufactured in Greece, by Athens-3, which was developed at the Athens Data Center Campus in Koropi.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.